Hospital
Baptist Health Deaconess Madisonville INC
Baptist Health Deaconess Madisonville INC was paid $80.89M by Medicaid between Jan 2018 and Dec 2024, across 442 billing codes. Its largest line is 99284, emergency room visit (serious) — 10.0% of everything it billed.
33Billing provider infoBAPTIST HEALTH DEACONESS MADISONVILLE INC
MADISONVILLE, KY 42431
MADISONVILLE, KY 42431
33aNPI1447231956assigned 11/10/2005
33bProvider typeRural Acute Care Hospital
28Total paid$80.89M
24GClaims1,716,876
24DCodes billed442
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Kentucky
Rank by total paid#2 of 10
Median peer was paid$23.35M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CARRICO, RICHARD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 247,817 | $12.59M | |
| 2019 | 243,749 | $11.59M | |
| 2020 | 220,887 | $10.13M | |
| 2021 | 280,682 | $12.41M | |
| 2022 | 275,230 | $11.70M | |
| 2023 | 269,142 | $12.63M | |
| 2024incomplete | 179,369 | $9.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10.0% | 28,306 | 22,933 | $8.06M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 35,357 | 29,880 | $7.16M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.1% | 59,471 | 17,823 | $4.94M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 7,750 | 6,612 | $3.80M |
| G0378 | Hospital observation service, per hour | 4.6% | 6,951 | 5,330 | $3.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.9% | 6,701 | 5,081 | $2.34M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.5% | 29,914 | 9,465 | $2.02M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.5% | 5,922 | 4,241 | $2.02M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.2% | 3,920 | 3,412 | $1.76M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 7,148 | 5,870 | $1.70M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.9% | 25,363 | 9,305 | $1.53M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 12,831 | 6,495 | $1.49M |
430 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 14,734 | $1.48M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 20,863 | $1.12M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.3% | 3,062 | $1.07M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.3% | 718 | $1.06M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.3% | 879 | $1.06M |
| 80053 | Comprehensive metabolic panel | 1.3% | 105,000 | $1.03M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 29,277 | $948K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.0% | 969 | $839K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,164 | $790K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,760 | $785K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,362 | $673K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 789 | $672K |
| 36415 | Collection of venous blood by venipuncture | <1% | 146,636 | $633K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,116 | $608K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,318 | $606K |
| 96376 | <1% | 8,693 | $591K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,348 | $589K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 84,444 | $589K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 4,034 | $580K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,813 | $552K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,334 | $535K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,543 | $535K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 11,983 | $532K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,224 | $525K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,414 | $520K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,547 | $506K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,539 | $493K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,730 | $484K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,837 | $465K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,964 | $461K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 20,523 | $453K |
| 80050 | General health panel | <1% | 10,517 | $422K |
| 59025 | Fetal non-stress test | <1% | 3,621 | $413K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,468 | $365K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 25,961 | $365K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,264 | $356K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 687 | $342K |
| 83880 | <1% | 9,756 | $339K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,078 | $337K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,373 | $325K |
| 97162 | <1% | 6,992 | $292K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,813 | $291K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 10,294 | $291K |
| 80061 | Lipid panel | <1% | 23,532 | $280K |
| 93971 | <1% | 1,262 | $265K | |
| 93017 | <1% | 857 | $255K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,544 | $249K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 3,119 | $245K |
| 86003 | <1% | 3,443 | $242K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 30,019 | $233K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,302 | $231K |
| 82607 | <1% | 19,671 | $226K | |
| C1769 | Guide wire | <1% | 2,584 | $226K |
| 74022 | <1% | 1,544 | $215K | |
| 43248 | <1% | 739 | $206K | |
| 84484 | <1% | 18,145 | $205K | |
| 96367 | <1% | 2,739 | $199K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 268 | $187K |
| 80081 | <1% | 2,413 | $187K | |
| 71250 | <1% | 1,285 | $186K | |
| 75574 | <1% | 600 | $186K | |
| 97161 | <1% | 3,675 | $184K | |
| 87480 | <1% | 8,710 | $182K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,760 | $180K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,657 | $170K |
| 72131 | <1% | 697 | $170K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 135 | $170K |
| 80306 | <1% | 11,084 | $163K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 432 | $163K |
| 73630 | <1% | 1,501 | $155K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 1,423 | $154K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 417 | $148K |
| 87510 | <1% | 8,239 | $146K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 649 | $143K |
| 84439 | <1% | 17,596 | $143K | |
| 73221 | <1% | 416 | $142K | |
| 0352U | <1% | 1,233 | $138K | |
| 73564 | <1% | 1,161 | $134K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,698 | $128K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 5,371 | $126K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16,621 | $125K |
| 74018 | <1% | 1,647 | $122K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,539 | $121K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,692 | $120K |
| 73610 | <1% | 1,174 | $115K | |
| 87660 | <1% | 6,228 | $112K | |
| 76775 | <1% | 533 | $108K | |
| 82728 | <1% | 9,611 | $107K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 945 | $106K |
| 86803 | <1% | 8,683 | $105K | |
| 83690 | <1% | 16,266 | $103K | |
| 73130 | <1% | 1,006 | $102K | |
| 93458 | <1% | 51 | $99K | |
| 83735 | <1% | 16,347 | $99K | |
| 84702 | <1% | 6,921 | $98K | |
| 80074 | <1% | 2,504 | $95K | |
| 92526 | <1% | 1,513 | $94K | |
| 87653 | <1% | 2,833 | $89K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,369 | $89K |
| 72100 | <1% | 1,113 | $88K | |
| 76830 | Ultrasound, transvaginal | <1% | 895 | $88K |
| 73030 | <1% | 1,094 | $87K | |
| 81001 | <1% | 25,347 | $83K | |
| 84466 | <1% | 7,711 | $80K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,967 | $79K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,326 | $79K |
| 76536 | <1% | 697 | $79K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,968 | $79K |
| 82746 | <1% | 6,365 | $76K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,932 | $74K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,426 | $74K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,891 | $73K |
| 83540 | <1% | 12,464 | $69K | |
| 93976 | <1% | 471 | $68K | |
| J2704 | Injection, propofol, 10 mg | <1% | 15,763 | $67K |
| 95800 | <1% | 391 | $66K | |
| 84403 | <1% | 2,871 | $65K | |
| 70486 | <1% | 278 | $64K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,264 | $64K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,063 | $62K |
| 78226 | <1% | 175 | $62K | |
| 85027 | <1% | 10,724 | $62K | |
| 87081 | <1% | 7,719 | $61K | |
| 0099U | <1% | 302 | $60K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 170 | $59K |
| 84703 | <1% | 7,529 | $56K | |
| 87040 | <1% | 5,714 | $56K | |
| 93975 | <1% | 202 | $56K | |
| 82962 | <1% | 15,185 | $55K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 454 | $52K |
| 83605 | <1% | 5,346 | $51K | |
| 85610 | <1% | 10,325 | $48K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,955 | $47K |
| 81025 | <1% | 7,644 | $45K | |
| 0100U | <1% | 76 | $45K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,797 | $44K |
| 47562 | <1% | 13 | $43K | |
| 80055 | <1% | 958 | $43K | |
| 92523 | <1% | 497 | $43K | |
| 82077 | <1% | 3,027 | $41K | |
| 84402 | <1% | 1,876 | $41K | |
| 83516 | <1% | 2,093 | $40K | |
| 82043 | <1% | 8,014 | $40K | |
| 85379 | <1% | 4,262 | $40K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 2,918 | $39K |
| 81003 | <1% | 17,658 | $38K | |
| 86850 | <1% | 4,813 | $38K | |
| 73110 | <1% | 346 | $37K | |
| 82670 | <1% | 1,261 | $36K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,245 | $34K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,419 | $34K |
| 93970 | <1% | 149 | $34K | |
| 80143 | <1% | 1,730 | $34K | |
| 87507 | <1% | 118 | $33K | |
| 84481 | <1% | 2,187 | $33K | |
| 83001 | <1% | 1,950 | $33K | |
| 90715 | <1% | 917 | $33K | |
| 97116 | <1% | 1,966 | $33K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,272 | $32K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,818 | $32K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,750 | $32K |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 414 | $31K |
| 82550 | <1% | 4,706 | $30K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 129 | $29K |
| 82570 | <1% | 6,708 | $29K | |
| 73562 | <1% | 337 | $29K | |
| 87186 | <1% | 3,642 | $28K | |
| 72128 | <1% | 123 | $28K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,471 | $28K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 3,500 | $27K |
| 0002A | <1% | 1,080 | $27K | |
| 73090 | <1% | 264 | $26K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,026 | $26K |
| 80179 | <1% | 1,692 | $26K | |
| 86038 | <1% | 2,348 | $25K | |
| 84146 | <1% | 1,461 | $25K | |
| 71271 | <1% | 350 | $25K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 645 | $25K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,304 | $24K |
| 83002 | <1% | 1,527 | $24K | |
| 82105 | <1% | 1,733 | $24K | |
| 97166 | <1% | 754 | $24K | |
| 72141 | <1% | 70 | $23K | |
| 87902 | <1% | 99 | $23K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,139 | $23K |
| 85730 | <1% | 3,989 | $23K | |
| 97533 | <1% | 864 | $23K | |
| 0001A | <1% | 1,165 | $23K | |
| 36591 | <1% | 818 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,461 | $22K |
| 83550 | <1% | 2,577 | $22K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 22 | $22K |
| 74019 | <1% | 259 | $22K | |
| 94760 | <1% | 3,160 | $21K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 92 | $21K |
| 88304 | <1% | 868 | $21K | |
| 73590 | <1% | 245 | $21K | |
| 58661 | <1% | 16 | $21K | |
| 86140 | <1% | 4,641 | $21K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 90 | $20K |
| 83970 | <1% | 668 | $20K | |
| 84480 | <1% | 1,512 | $19K | |
| 82785 | <1% | 1,094 | $19K | |
| 86900 | <1% | 5,460 | $19K | |
| 86757 | <1% | 588 | $18K | |
| 83883 | <1% | 1,487 | $18K | |
| 12001 | <1% | 168 | $18K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,103 | $18K |
| 82172 | <1% | 1,151 | $17K | |
| 87077 | <1% | 2,405 | $17K | |
| 70498 | <1% | 88 | $17K | |
| 82948 | <1% | 2,674 | $17K | |
| 83655 | <1% | 1,524 | $17K | |
| 87070 | <1% | 2,553 | $17K | |
| 83525 | <1% | 1,630 | $17K | |
| 88342 | <1% | 376 | $16K | |
| 86901 | <1% | 5,025 | $16K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 64 | $16K |
| 86008 | <1% | 1,499 | $15K | |
| 82803 | <1% | 872 | $15K | |
| 87641 | <1% | 527 | $15K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,654 | $15K |
| 82150 | <1% | 2,284 | $15K | |
| 78227 | <1% | 31 | $15K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,962 | $14K |
| 70496 | <1% | 59 | $14K | |
| 82950 | <1% | 2,988 | $13K | |
| 84145 | <1% | 641 | $13K | |
| 0003M | <1% | 180 | $13K | |
| 86235 | <1% | 122 | $13K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 194 | $13K |
| 87147 | <1% | 1,609 | $13K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,751 | $12K |
| 82627 | <1% | 484 | $12K | |
| 96368 | <1% | 106 | $12K | |
| 81596 | <1% | 157 | $12K | |
| 84100 | <1% | 2,836 | $11K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 128 | $11K |
| 86592 | <1% | 1,978 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,019 | $11K |
| 84156 | <1% | 3,383 | $11K | |
| 86618 | <1% | 518 | $11K | |
| 94060 | <1% | 150 | $11K | |
| 87340 | <1% | 1,289 | $11K | |
| 86376 | <1% | 854 | $11K | |
| 87807 | <1% | 697 | $10K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 111 | $10K |
| J0897 | Injection, denosumab, 1 mg | <1% | 16 | $10K |
| J3490 | Unclassified drugs | <1% | 115 | $10K |
| 86696 | <1% | 537 | $9K | |
| 82784 | <1% | 886 | $9K | |
| 84144 | <1% | 510 | $9K | |
| 83010 | <1% | 883 | $9K | |
| 97113 | <1% | 86 | $9K | |
| 78264 | <1% | 14 | $9K | |
| 36600 | <1% | 409 | $9K | |
| 80069 | <1% | 1,194 | $9K | |
| 88300 | <1% | 549 | $8K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 40 | $8K |
| 73502 | <1% | 143 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 110 | $8K |
| 82533 | <1% | 372 | $8K | |
| 86364 | <1% | 666 | $8K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,266 | $8K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,316 | $7K |
| 97035 | <1% | 213 | $7K | |
| 88142 | <1% | 351 | $7K | |
| 82977 | <1% | 1,187 | $7K | |
| 86695 | <1% | 489 | $7K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,725 | $6K |
| 87205 | <1% | 1,688 | $6K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 893 | $6K |
| 86258 | <1% | 484 | $6K | |
| 84550 | <1% | 1,464 | $6K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 66 | $6K |
| 80076 | <1% | 785 | $6K | |
| 86666 | <1% | 145 | $6K | |
| 82247 | <1% | 1,240 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 418 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,915 | $5K |
| 82553 | <1% | 510 | $5K | |
| 87631 | <1% | 41 | $5K | |
| 0097U | <1% | 30 | $5K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 980 | $5K |
| 82565 | <1% | 414 | $5K | |
| 76870 | <1% | 47 | $5K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 477 | $5K |
| 85652 | <1% | 1,812 | $5K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 15 | $4K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 395 | $4K |
| 73700 | <1% | 12 | $4K | |
| 85014 | <1% | 2,140 | $4K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 544 | $4K |
| 73080 | <1% | 43 | $4K | |
| 85651 | <1% | 1,067 | $4K | |
| 97597 | <1% | 23 | $4K | |
| 82140 | <1% | 383 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,115 | $4K |
| 85018 | <1% | 1,888 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 81 | $4K |
| 82024 | <1% | 102 | $4K | |
| 86431 | <1% | 633 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,553 | $4K |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 2,044 | $3K |
| 94727 | <1% | 64 | $3K | |
| 76770 | <1% | 30 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,039 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,024 | $3K |
| 92610 | <1% | 43 | $3K | |
| 84478 | <1% | 656 | $3K | |
| 80164 | <1% | 314 | $3K | |
| 84153 | <1% | 213 | $3K | |
| 87088 | <1% | 396 | $3K | |
| 83721 | <1% | 408 | $3K | |
| 83615 | <1% | 530 | $3K | |
| 12002 | <1% | 35 | $3K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 13 | $3K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 28 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 100 | $3K |
| 87581 | <1% | 90 | $2K | |
| 82951 | <1% | 248 | $2K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 716 | $2K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 517 | $2K |
| 84132 | <1% | 583 | $2K | |
| 82248 | <1% | 445 | $2K | |
| 84436 | <1% | 386 | $2K | |
| 94729 | <1% | 45 | $2K | |
| 93325 | <1% | 14 | $2K | |
| 82677 | <1% | 76 | $2K | |
| 29580 | <1% | 23 | $2K | |
| 86762 | <1% | 171 | $2K | |
| 96523 | <1% | 125 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 827 | $2K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,916 | $2K |
| 82465 | <1% | 580 | $2K | |
| 97165 | <1% | 81 | $2K | |
| 86225 | <1% | 143 | $2K | |
| 71101 | <1% | 12 | $2K | |
| 82947 | <1% | 647 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 415 | $2K |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 12 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 21 | $2K |
| 84520 | <1% | 278 | $2K | |
| 81513 | <1% | 16 | $2K | |
| 76801 | <1% | 12 | $2K | |
| 97163 | <1% | 33 | $1K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 555 | $1K |
| 83527 | <1% | 130 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 167 | $1K |
| 86336 | <1% | 81 | $1K | |
| 88307 | <1% | 21 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 150 | $1K |
| 81050 | <1% | 355 | $1K | |
| 84445 | <1% | 30 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 25 | $1K |
| 72040 | <1% | 25 | $1K | |
| 86769 | <1% | 44 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $1K |
| 84460 | <1% | 281 | $1K | |
| 86706 | <1% | 114 | $1K | |
| 94664 | <1% | 40 | $1K | |
| 84681 | <1% | 45 | $978.79 | |
| 87486 | <1% | 41 | $964.15 | |
| 76937 | <1% | 14 | $960.23 | |
| 97602 | <1% | 24 | $941.26 | |
| 76942 | <1% | 18 | $902.96 | |
| 84450 | <1% | 230 | $857.62 | |
| 82009 | <1% | 213 | $819.83 | |
| 86381 | <1% | 53 | $814.40 | |
| 97164 | <1% | 27 | $793.80 | |
| 86480 | <1% | 12 | $792.26 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 16 | $772.84 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 104 | $717.07 |
| G0008 | Administration of influenza virus vaccine | <1% | 71 | $692.16 |
| 86015 | <1% | 68 | $633.35 | |
| 82805 | <1% | 18 | $633.32 | |
| 82952 | <1% | 218 | $628.61 | |
| 82672 | <1% | 16 | $560.77 | |
| L3020 | Foot, insert, removable, molded to patient model, longitudinal/ metatarsal support, each | <1% | 17 | $534.50 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 149 | $527.77 |
| 86704 | <1% | 43 | $514.53 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 29 | $506.14 |
| 85007 | <1% | 193 | $498.04 | |
| 99152 | <1% | 13 | $495.53 | |
| 86677 | <1% | 13 | $488.65 | |
| 88302 | <1% | 20 | $466.44 | |
| 90674 | <1% | 29 | $462.20 | |
| 84270 | <1% | 27 | $453.19 | |
| 90661 | <1% | 17 | $441.42 | |
| L8613 | Ossicula implant | <1% | 14 | $433.78 |
| 86308 | <1% | 70 | $428.48 | |
| 36416 | <1% | 127 | $408.96 | |
| 86231 | <1% | 47 | $398.97 | |
| 86665 | <1% | 17 | $397.10 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 13 | $391.49 |
| 81015 | <1% | 128 | $373.02 | |
| 82390 | <1% | 40 | $365.16 | |
| 87484 | <1% | 15 | $350.90 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 17 | $346.61 |
| 97168 | <1% | 27 | $339.06 | |
| 87481 | <1% | 17 | $326.04 | |
| 87468 | <1% | 14 | $315.81 | |
| 82103 | <1% | 26 | $309.12 | |
| 80171 | <1% | 22 | $304.67 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 203 | $301.41 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 17 | $267.41 |
| 86787 | <1% | 25 | $259.53 | |
| 97750 | <1% | 16 | $259.42 | |
| 86430 | <1% | 47 | $249.92 | |
| 90686 | <1% | 37 | $247.95 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 47 | $221.30 |
| 86800 | <1% | 13 | $217.21 | |
| 83021 | <1% | 15 | $190.60 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 53 | $179.51 |
| 82375 | <1% | 25 | $168.59 | |
| 80162 | <1% | 18 | $165.55 | |
| 86664 | <1% | 13 | $161.40 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 19 | $143.92 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 77 | $142.53 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 16 | $119.13 |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 17 | $116.52 |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | <1% | 38 | $113.84 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 44 | $110.61 |
| 84479 | <1% | 12 | $88.88 | |
| 83050 | <1% | 18 | $72.76 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 14 | $62.00 |
| 85660 | <1% | 15 | $52.03 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 39 | $16.58 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 18 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRICO, RICHARD (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.